Seeking Alpha

Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting

WATERTOWN, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of ...
Seeking Alpha

Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

First-in-kind real-time pharmacokinetic data in a mouse tumor model confirmed WTX-124 selective activation in tumors, sparing healthy tissue WATERTOWN, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- ...
Hosted on MSN

Werewolf Therapeutics updates pipeline and outlines 2026 priorities

The latest update is out from Werewolf Therapeutics ( (HOWL)). On December 18, 2025, Werewolf Therapeutics reported a pipeline update and 2026 business priorities centered on its INDUKINE and INDUCER ...
Nasdaq

Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer

Appointment of Steven Bloom as Chief Business Officer brings over 35 years of life sciences industry experience, which could enhance Werewolf's strategic development and business initiatives. Bloom's ...